Furthermore, our findings showed that combination therapy with anti-PD-L1 antibody and TLR-7/8 agonist also required CD40 positive B cells and their chemokine CXCL13 to generate optimum anti-melanoma immunity. Here, CXCL13 is linked to melanoma.